Fresenius Kabi Oncology executes SPA with Fresenius Kabi AG

28 Jun 2011 Evaluate

Fresenius Kabi Oncology has finalized and executed the share purchase agreement (SPA) with Fresenius Kabi AG with effect from June 24, 2011. As per the share purchase agreement, Fresenius Kabi Oncology's entire shareholding of 171,400,000 equity shares of GBP 0.10 each in Fresenius Kabi Oncology Plc, UK now stands transferred to Fresenius Kabi AG (Germany) at the book value, which is not less than the fair market value. Subsequent to this disinvestment, the company does not have any other subsidiary.

Earlier, Fresenius Kabi Oncology had received an approval at its board meeting held on May 26, 2011 for disinvestment of its entire shareholding in Fresenius Kabi Oncology Plc, UK - a wholly owned subsidiary of the company to Fresenius Kabi Germany and its affiliates. The agreements would come into effect after obtaining all necessary internal approvals and signing of the same, which can be expected in June 2011.

Fresenius Kabi Oncology is a leading Indian company for cancer research and anticancer products. The company uses the services of Dabur Research Foundation (DRF) for research and development activities. The pharma major market its products in various parts of the world namely Bangladesh, Sri Lanka, Thailand, Philippines, Malaysia, Vietnam, Myanmar, Jordan, Russia, Ukraine, Georgia, Kazakhstan, Uzbekistan, Hungary, Kenya, Nigeria, Ghana, Zimbabwe, Brazil, Venezuela and Mexico, among others.

Peers
Company Name CMP
Sun Pharma Inds. 1530.00
Dr. Reddys Lab 5802.00
Cipla 1399.35
Zydus Lifesciences 1051.90
Lupin 1653.75
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.